Skip to main content
    E

    Evolent Health Inc (EVH)

    Official site

    HEALTHCARE • HEALTH INFORMATION SERVICES • NYSE

    $4.83
    -0.07 (-1.53%)

    Market Cap: $554.22M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Evolent Health Inc (EVH) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Evolent Health (EVH) to earn $0.24 per share in the fiscal year ending Dec 31, 2026, on revenue of $2.64B. Of 14 analysts, 11 rate the stock Buy or Strong Buy, 3 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 14 ratings average 1.93, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 79% of the ratings.

    RatingAnalystsShare
    Strong Buy428.6%
    Buy750.0%
    Hold321.4%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    14

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 75.0% and revenue estimates rise 25.8%.

    Fiscal year ending Dec 31, 2026
    $0.24
    EPS consensus, revenue $2.64B
    Fiscal year ending Dec 31, 2027
    $0.42
    EPS consensus, revenue $3.32B
    Next report
    Feb 22, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.24$0.20 to $0.279$2.64B$2.61B to $2.68B14
    Dec 31, 2027$0.42$0.28 to $0.599$3.32B$3.13B to $3.55B14

    Quarterly Estimates

    The EPS consensus falls from $0.16 for the quarter ending Dec 31, 2026 to $0.07 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.16$0.07 to $0.2216$767.96M$702.66M to $827.74M16
    Mar 31, 2027$0.07$0.01 to $0.136$795.70M$688.15M to $893.03M10

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 7 upward and 7 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202755
    Quarter ending Mar 31, 202712

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 26.3% from $0.19.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$0.24$0.20$0.20$0.20$0.19+22.1%
    Fiscal year ending Dec 31, 2027$0.42$0.40$0.40$0.39$0.39+9.6%
    Quarter ending Mar 31, 2027$0.07$0.07$0.07$0.07$0.06+10.2%

    Frequently Asked Questions About EVH

    What is the EVH stock forecast?

    Consensus analyst estimates put Evolent Health's EPS at $0.24 for the fiscal year ending Dec 31, 2026, on revenue of $2.64B. The consensus rating from 14 analysts is Buy.

    How do analysts rate EVH stock?

    Of 14 analysts covering Evolent Health, 4 rate it Strong Buy, 7 Buy, 3 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from EVH next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.24, with estimates from $0.20 to $0.27 from 9 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.42, with estimates from $0.28 to $0.59 from 9 analysts.

    What revenue do analysts expect from Evolent Health next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $2.64B, with estimates from $2.61B to $2.68B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $3.32B, with estimates from $3.13B to $3.55B.

    How many analysts cover EVH?

    14 analysts rate Evolent Health stock, and 9 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.